Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes

Cancer Research

Volumn 64, Issue 11, 2004, Pages 4010-4017

  Kawada, Kenji ^a   Sonoshita, Masahiro ^a   Sakashita, Hiromi ^a   Takabayashi, Arimichi ^b   Yamaoka, Yoshio ^a   Manabe, Toshiaki ^a   Inaba, Kayo ^a   Minato, Nagahiro ^a   Oshima, Masanobu ^a   Taketo, Makoto Mark ^a  

^a KYOTO UNIVERSITY   (Japan)

^b Kitano Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR CXCR3; COMPLEMENTARY RNA; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; FREUND ADJUVANT; GAMMA INTERFERON INDUCIBLE PROTEIN 10; UNCLASSIFIED DRUG;

ACTIN POLYMERIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MIGRATION; CELL SURVIVAL; CHEMOTAXIS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; ISOGRAFT; LYMPH NODE METASTASIS; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACTINS; ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CHEMOKINES, CXC; CYTOSKELETON; FOCAL ADHESIONS; FREUND'S ADJUVANT; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; NEOPLASM INVASIVENESS; RECEPTORS, CHEMOKINE; RNA, MESSENGER; TRANSFECTION;

EID: 2542612840     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-1757     Document Type: Article

References (48)

1. McCarthy WH, Shaw HM, Thompson JF, Milton GW. Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow-up study. Surg Gynecol Obstet 1988;166:497-502.
2. Fisher B, Fisher ER. The interrelationship of hematogenous and lymphatic tumor cell dissemination. Surg Gynecol Obstet 1966;122:791-8.
3. Gendreau KM, Whalen GF. What can we learn from the phenomenon of preferential lymph node metastasis in carcinoma?. J Surg Oncol 1999;70:199-204.
4. Coit DG, Rogatko A, Brennan MF. Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes. A multivariate analysis. Ann Surg 1991;214:627-36.
5. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
6. Wang JM, Deng X, Gong W, Su S. Chemokines and their role in tumor growth and metastasis. J Immunol Methods 1998;220:1-17.
7. Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-6.
8. Wiley HE, Gonzalez EB, Maki W, Wu M, Hwang ST. Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J Natl Cancer Inst 2001;93:1638-43.
9. Scotton CJ, Wilson JL, Milliken D, Stamp G, Balkwill FR. Epithelial cancer cell migration: A role for chemokine receptor? Cancer Res 2001;61:4961-5.
10. Robledo MM, Bartolome RA, Longo N, et al. Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells. J Biol Chem 2001;276:45098-105.
11. Trentin L, Agostini C, Facco M, et al. The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis. J Clin Investig 1999;104:115-21.
12. Saiki 1, Murata J, Nakajima M, Tokura S, Azuma I. Inhibition by sulfated chitin derivatives of invasive through extracellular matrix and enzymatic degradation by metastatic melanoma cells. Cancer Res 1990;50:3631-7.
13. Hujanen ES, Terranova VP. Migration of tumor cells to organ-derived chemoattractants. Cancer Res 1985;45:3517-21.
14. Whalen GF, Sharif SF. Locally increased metastatic efficiency as a reason for preferential metastasis of solid tumors to lymph nodes. Ann Surg 1992;215:166-71.
15. Jenh C-H, Cox MA, Kaminski H, et al. Cutting edge: species specificity of the CC chemokine 6Ckine signaling through the CXC chemokine receptor CXCR3: human 6Ckine is not a ligand for the human, or mouse CXCR3 receptors. J Immunol 1999;162:3765-9.
16. Lu B, Humbles A, Bota D, et al. Structure and function of the murine chemokine receptor CXCR3. Eur J Immunol 1999;29:3804-12.
17. Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1(SDF-1). J Exp Med 1996;184:1101-9.
18. Craig SW, Johnson RP. Assembly of focal adhesions: progress, paradigms, and portents. Curr Opin Cell Biol 1996;8:74-85.
19. Turner CE. Paxillin and focal adhesion signalling. Nature Cell Biol 2000;2:E231-6.
20. Barbero S, Bonavia R, Bajetto A, et al. Stromal cell-derived factor 1α stimulates human glioblastoma cell growth through the activation of both extracellular signal-regulated kinases 1/2 and Akt. Cancer Res 2003;63:1969-74.
21. Vlahakis SR, Villasis-Keever A, Gomez T, Vanegas M, Vlahakis N, Paya CV. G protein-coupled chemokine receptors induce both survival and apoptotic signaling pathways. J Immunol 2002;169:5546-54.
22. Burger JA, Burger M, Kipps TJ. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 1999;94:3658-67.
23. Bieligk SC, Ghossein R, Bhattacharya S, Coit DG. Detection of tyrosinase mRNA by reverse transcription-polymerase chain reaction in melanoma sentinel nodes. Ann Surg Oncol 1999;6:232-40.
24. Gattass CR, King LB, Luster AD, Ashwell JD. Constitutive expression of interferon γ-inducible protein 10 in lymphoid organs and inducible expression in T cells and thymocytes. J Exp Med 1994;179:1373-8.
25. Amichay D, Gazzinelli RT, Karupiah G, Moench TR, Sher A, Farber JM. Genes for chemokines MuMig and Crg-2 are induced in protozoan and viral infections in response to IFN-γ with patterns of tissue expression that suggest nonredundant roles in vivo. J Immunol 1996;157:4511-20.
26. Janatpour MJ, Hudak S, Sathe M, Sedgwick JD, McEvoy LM. Tumor necrosis factor-dependent segmental control of MIG expression by high endothelial venules in inflamed lymph nodes regulates monocyte recruitment. J Exp Med 2001;193:1375-84.
27. Billiau A, Matthys P. Modes of action of Freund's adjuvants in experimental models of autoimmune diseases. J Leukoc Biol 2001;70:849-60.
28. Homey B, Wang W, Soto H, et al. Cutting edge: the orphan chemokine receptor G protein-coupled receptor-2 (GPR-2, CCR10) binds the skin-associated chemokine CCL27 (CTACK/ALP/ILC). J Immunol 2000;164:3465-70.
29. Weiss L. The pathobiology of metastasis within the lymphatic system. Surg Oncol Clin North Am 1996;5:15-24.
30. Fidler IJ, Kripke ML. Metastasis results from pre-existing variant cells within a malignant tumor. Science 1977;197:893-5.
31. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nature Rev Cancer 2002;2:563-72.
32. Kang Y, Siegel PM, Shu W, et al. A mutigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3:537-49.
33. Murakami T, Maki W, Cardones AR, et al. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res 2002;62:7328-34.
34. Fidler IJ. Selection of successive tumour lines for metastasis. Nature New Biol 1973;242:148-9.
35. Pardoll D. T cells and tumours. Nature 2001;411:1010-2.
36. Ochsenbein AF, Sierro S, Odermatt B, et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 2001;411:1058-64.
37. Oka M, Yoshino S, Hazama S, Shimoda K, Suzuki M, Suzuki T. Prognostic significance of regional lymph node reaction after curative resection of advanced gastric cancer. Br J Surg 1992;79:1091-4.
38. Giorgio AD, Mingazzini P, Sammartino P, Canavese A, Arnone P, Scarpini M. Host defense and survival in patients with lung carcinoma. Cancer 2000;89:2038-45.
39. Rossi D, Zlotnik A. The biology of chemokines and their receptors, Annu Rev Immunol 2000;18:217-42.
40. Farber JM. A macrophage mRNA selectively induced by γ-interferon encodes a member of the platelet factor 4 family of cytokines. Proc Natl Acad Sci USA 1990;87:5238-42.
41. Luster AD, Unkeless JC, Ravetch JV. γ-interferon transcriptionally regulates an early response gene containing homology to platelet protein. Nature 1985;315:672-6.
42. Cole KE, Strick CA, Paradis TJ, et al. Interferon-inducible T cell α chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 1998;187:2009-21.
43. Tannenbaum CS, Tubbs R, Armstrong D, Finke JH, Bukowski RM, Hamilton TA. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J Immunol 1998;161:927-32.
44. Ruehlmann JM, Xiang R, Niethammer AG, et al. MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma. Cancer Res 2001;61:8498-503.
45. Sgadari C, Farber JM, Angiolillo AL, et al. Mig, the monokine induced by interferon-γ promotes tumor necrosis in vivo. Blood 1997;89:2635-43.
46. Negus RPK, Stamp GWO, Hadley J, Balkwill FR. Quantitative assessment of the leukocyte infiltrate on ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol 1997;150:1723-34.
47. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-45.
48. Tsung K, Dolan JP, Tsung YL, Norton JA. Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection. Cancer Res 2002;62:5069-75.